Applied Therapeutics, Inc. (APLT): Price and Financial Metrics

Applied Therapeutics, Inc. (APLT): $0.87

0.03 (+3.57%)

POWR Rating

Component Grades













APLT Stock Price Chart Interactive Chart >

Price chart for APLT

APLT Price/Volume Stats

Current price $0.87 52-week high $10.77
Prev. close $0.84 52-week low $0.50
Day low $0.80 Volume 176,300
Day high $0.89 Avg. volume 374,998
50-day MA $0.79 Dividend yield N/A
200-day MA $1.33 Market Cap 41.81M

Applied Therapeutics, Inc. (APLT) Company Bio

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY

APLT Latest News Stream

Event/Time News Detail
Loading, please wait...

APLT Latest Social Stream

Loading social stream, please wait...

View Full APLT Social Stream

Latest APLT News From Around the Web

Below are the latest news stories about APPLIED THERAPEUTICS INC that investors may wish to consider to help them evaluate APLT as an investment opportunity.

Applied Therapeutics Reports Third Quarter 2022 Financial Results

NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2022. “In the third quarter, we made significant progress across all three of our late-stage programs,” said Shoshana Shendelman, PhD, Founder, CEO and C

Yahoo | November 9, 2022

Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022

Additional preclinical data supports AT-001 as an effective treatment for Diabetic Cardiomyopathy, reducing cardiac fibrosis and adverse remodelingBaseline analysis of Phase 3 ARISE-HF study supports the primary endpoint (cardiac functional capacity as measured by Peak VO2) as an important metric of quality of life and physical functioning in Diabetic Cardiomyopathy patients NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical

Yahoo | October 31, 2022

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

ARISE-HF is a global registrational study in 675 patients with Diabetic Cardiomyopathy (DbCM), evaluating the potential of AT-001 to improve or prevent worsening of cardiac function vs. placeboPrimary study endpoint is cardiac functional capacity (measured by Peak VO2) at 15 monthsDbCM is a form of heart failure affecting approximately 20% of Type 2 Diabetes patients (~6M patients in the US and ~5M in EU), which represents a significant commercial market opportunityThere are currently no treatme

Yahoo | October 25, 2022

Insiders who purchased Applied Therapeutics, Inc. (NASDAQ:APLT) earlier this year lose an additional US$86k as the stock sinks to US$0.62

The recent price decline of 33% in Applied Therapeutics, Inc.'s ( NASDAQ:APLT ) stock may have disappointed insiders...

Yahoo | October 9, 2022

Applied Therapeutics' Lead Candidate Pediatric Study Failed To Reach Statistical Significance

Applied Therapeutics Inc's (NASDAQ: APLT) ACTION-Galactosemia Kids Phase 3 trial has demonstrated a trend in clinical benefit favoring AT-007 vs. placebo. The study is designed to evaluate the impact of AT-007 vs. placebo on clinical outcomes in children with Classic Galactosemia, with a review of safety and efficacy every six months. Classic galactosemia is an inherited condition in which the body cannot properly digest galactose, a sugar found in all foods containing milk. The sugar buildup ca

Yahoo | October 6, 2022

Read More 'APLT' Stories Here

APLT Price Returns

1-mo 33.89%
3-mo -40.41%
6-mo -37.86%
1-year -91.10%
3-year -95.85%
5-year N/A
YTD -90.28%
2021 -59.34%
2020 -19.32%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6041 seconds.